Cytokinetics (CYTK) FY2024 results: revenue $18 million, up 145.3% on the year
Cytokinetics Inc. (CYTK) reported revenue of $18 million for fiscal 2024, the year ended 31 December 2024, up 145.3% on the year before. Net income was -$590 million, and diluted earnings per share $-5.26. The figures are the company's own, from the 10-K it filed with the SEC on 27 February 2025.
Revenue
$18 million
+145.3% on the year
FY2017FY2024
Operating margin
-2902.7%
-6589.7% a year earlier
FY2017FY2024
Net income
-$590 million
FY2017FY2024
Diluted EPS
-$5.26
FY2017FY2024
this yearthe year beforeHover a bar for its figure.
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2024
FY2023
FY2022
On the year
Last 8 years
Operating cash flow
-396
-414
-300
Capital expenditure
3.9
1.4
11.3
+175.8%
Free cash flow
-400
-416
-311
Free cash flow margin
-2164.1%
-5521.2%
-328.6%
Cash from investing
-553
239
-262
Cash from financing
931
221
516
+320.5%
Depreciation and amortisation
9.5
11.9
5.8
-19.9%
Share-based compensation
97.8
72.1
47.9
+35.8%
Diluted shares, weighted
112m
97m
90m
+16.0%
Shares outstanding at period end
118m
102m
95m
+16.3%
Balance sheet
$ million
FY2024
FY2023
FY2022
On the year
Last 8 years
Shareholders' equity
-135
-386
-108
Debt
657
639
650
+2.8%
Operating lease liabilities
113
120
127
-6.5%
Other liabilities
767
451
346
+70.2%
Total liabilities and equity
1,402
824
1,015
+70.0%
Fixed assets
65.8
68.7
80.5
-4.3%
Investments
1,126
542
764
+107.7%
Cash and equivalents
94.9
113
65.6
-16.1%
Receivables
16.6
1.3
0.1
+1,197.7%
Other assets
98.1
98.9
105
-0.8%
Total assets
1,402
824
1,015
+70.0%
10-K for the year ended 31 December 2024, filed 27 February 2025: the filing.